Drug Trial Radar · NCT04591405
Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11
Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
11,999
Actual
Start
Oct 12, 2020
Primary completion
Jul 1, 2024
Study completion Jul 1, 2024
Sponsor
- Lead sponsor
- Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hubei Provincial Center for Disease Control and Prevention
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 11 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Mumps is an acute infectious respiratory disease caused by the mumps virus (MuV), which occurs mainly in children and adolescents. Its main clinical symptoms were parotid gland suppurative swelling and pain with fever. The pathological changes and harm caused by mumps was not only confined to the parotid gland, on the contrary, the social harm caused by serious complications cannot be ignored. As mumps is a vaccine-preventable infectious disease, vaccination is a fundamental strategy for controlling mumps. So far, there are 13 genotypes of MuV. Based on the analysis of molecular epidemiology, the main epidemic strain of MuV in China was the F genotype. The commonly used vaccine strains represented only a small number of known genotypes, e.g. Jeryl-Lynn (JL) and Rubini strains, which belong to type A, Urabe strain belongs to type B, and L-Zagreb strains belongs to type D. Virus seed of Live Attenuated Mumps Vaccine (Human diploid cell) developed by the institute was SP-A strain, which was the first separation and preparation of the attenuated mumps viruses in China. SP-A belongs to F genotype, which was the domestic epidemic genotype. In addition, the cell substrate prepared for vaccine was human diploid cell (KMB-17 strain), which is much safer to use. The results of phase I and II clinical trials showed that the vaccine possessed good immunogenicity and good antigenic cross-reactivity in infants (8-24 months old).
Conditions
- Epidemic Parotitis, Mumps
Interventions
Attenuated Mumps vaccine (KMB-17) in phase II and IIIBiological
≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day
Placebo in phase IIBiological
Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
Attenuated Mumps vaccine (KMB-17) in phase IIIBiological
≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day
Placebo in phase IIIBiological
Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase II: Positive conversion rate of MuV hemagglutination inhibition antibody of Muv VaccineTime frame: 28 day after the vaccination
- Phase II: Positive conversion rate of MuV neutralization antibody of MuV VaccineTime frame: 28 day after the vaccination
- Phase III: The protective effect of the MuV vaccine group compared with the placebo group in preventing mumps according with the protocolTime frame: within 12 months after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.